The Mark Foundation for Cancer Research recently launched our inaugural RFP for the Emerging Leader Awards.
This information was made available on our website and also sent to you via an external marketing platform. This email is to ensure that you are in receipt of the attached Guidelines and FAQs for these signature three-year, $750,000 academic awards. Letters of Intent are due Monday, June 4.
Emerging Leader Awards_Guidelines_MFCR
FAQs_Emerging Leader Awards 2018_Final
Communications may be addressed to Chief Grants Management & Communications Officer:
The Mark Foundation for Cancer Research
10 East 53rd Street, Floor 13
New York, NY 10022
(646) 866-5950 Main
(646) 866-5947 Direct
The National MS Society is seeking proposals for innovative research with relevance to our Research Priorities, and applications for research training and early career awards.
DEADLINES ARE APPROACHING:
Research Grants – pre-applications due July 25; full applications due
August 1, 5:00 pm EST
Collaborative MS Research Centers – pre-applications due August 30; full applications due September 5, 5:00 pm EST
Pilot Research Grants – pre-applications due September 10; full applications due September 12
TRAINING/EARLY CAREER AWARDS
Mentor-Based Postdoctoral Fellowships In Rehabilitation Research –
pre-applications due July 25; full applications due August 1, 5:00 pm EST
Postdoctoral Fellowships – pre-applications due August 8; full applications due August 15, 5:00 pm EST
Sylvia Lawry Physician Fellowships – pre-applications due August 8; full applications due August 15, 5:00 pm EST
NMSS-ABF MS Clinician Scientist Development Awards – pre-applications due August 8; full applications due August 15, 5:00 pm EST
Harry Weaver Neuroscience Scholar Awards – pre-applications due August 8; full applications due August 15, 5:00 pm EST
Please visit our Website to obtain detailed information about these funding opportunities.
FY18 PRMRP Program Announcements and General Application Instructions for the following award mechanism is posted on Grants.gov
As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
Congressionally Directed Topic Areas. All applications submitted to the PRMRP must address at least one of the FY18 PRMRP Congressionally directed topic areas.
Topic Areas are as follows:
- Acute Lung Injury
- Antimicrobial Resistance
- Burn Pit Exposure
- Cerebellar Ataxia
- Chronic Migraine and Post-Traumatic Headache
- Chronic Pain Management
- Congenital Heart Disease
- Constrictive Bronchiolitis
- Eating Disorders
- Emerging Infectious Diseases
- Epidermolysis Bullosa
- Focal Segmental Glomerulosclerosis
- Fragile X Syndrome
- Guillain-Barré Syndrome
- Hepatitis B and C
- Hereditary Angioedema
- Immunomonitoring of Intestinal Transplants
- Inflammatory Bowel Diseases
- Interstitial Cystitis
- Lung Injury
- Metals Toxicology
- Mitochondrial Disease
- Musculoskeletal Disorders
- Myotonic Dystrophy
- Non-Opioid Pain Management
- Nutrition Optimization
- Pathogen-Inactivated Blood Products
- Post-Traumatic Osteoarthritis
- Pressure Ulcers
- Pulmonary Fibrosis
- Respiratory Health
- Rett Syndrome
- Rheumatoid Arthritis
- Sleep Disorders
- Spinal Muscular Atrophy
- Sustained-Release Drug Delivery
- Vascular Malformations
- Women’s Heart Disease
The mission of the PRMRP is to encourage, identify, and select military health-related research of exceptional scientific merit. Relevance to the healthcare needs of military Service members, Veterans, and their family members is a key feature of each FY18 PRMRP award mechanism.
Clinical Trial Award
- Assistant Professor level or above (or equivalent)
- Preproposal submission is required; application submission is by invitation only.
- Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
- Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
- Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration by the PRMRP application submission deadline.
- Funding limit not defined; requested funding must be appropriate for the scope of work proposed
- Maximum period of performance is 4 years
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Applications must be submitted through the federal government’s single-entry portal, Grants.gov.. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
Point of Contact:
CDMRP Help Desk